Victoria Barajas
Family · Crown Point, INNPI 1487098935
Payments from drug & device makers
Across 531 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Mannkind Corporation$990
- Recordati_rare_diseases_inc.$920
- AbbVie$758
- Ascensia Diabetes Care US Inc.$728
- Novo Nordisk$655
- plus $6K from 39 others
What the payments were for
- Travel & lodging$7086%
- Food & beverage$10,69693%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$623
- INPEN SMART INSULIN DELIVERY SYSTEM$515
- iLet Bionic Pancreas$317
- CeQur Simplicity$199
- Yorvipath$125
- REZDIFFRA$110
- Korlym$108
How this compares
$11,440 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 191 | $359,522 |
| MounjaroTirzepatide | 85 | $155,353 |
| JardianceEmpagliflozin | 66 | $89,352 |
| FarxigaDapagliflozin Propanediol | 55 | $60,179 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $54,929 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $39,797 |
| RybelsusSemaglutide | 15 | $36,457 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $31,905 |
| JanuviaSitagliptin Phosphate | 33 | $29,698 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $26,470 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $25,088 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $21,512 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $21,175 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $18,922 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 19 | $14,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $655 | $406,000227 claims |
| Lilly USA, LLCMounjaro, Humalog | $367 | $162,857103 claims |
| Boehringer IngelheimJardiance | $348 | $89,35266 claims |
| AstraZenecaFarxiga | $463 | $60,17955 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $332 | $39,79724 claims |
| MerckJanuvia | $42 | $29,69833 claims |
| AbbVieSynthroid, Armour Thyroid | $758 | $14,060130 claims |
| IBSA Pharma Inc.Tirosint | $49 | $3,19111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $202 | $3,097341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Crown Point
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.